In severe cases of COVID-19, the immune system overreacts to the infection and releases inflammatory molecules called cytokines into the bloodstream. This so-called “cytokine storm” can damage many organs, including the heart.
The Canadian company Resverlogix has used the results of the QIMR Berghofer study as a basis for expanding the clinical trial of the drug, apabetalone, in COVID-19 patients.
QIMR Berghofer Head of Cardiac Biotechnology Research Group, Assistant Professor James Hudson, said his team used thousands of laboratory-grown, small-sized human heart organoids to understand how COVID-19 causes heart damage.
“We exposed COVID-19 to the blood of a patient with biotechnology, a heart tissue derived from stem cells, and found that it caused dysfunction even though the virus did not infect the tissue.”
CEO of Resverlogix Donald McCaffrey, said it had been a pleasure to work with the QIMR Berghofer team.
“We are excited to finally be able to publicly share some of the amazing early results of our COVID-19 research program,” McCaffrey said.
Source: The Nordic Page